Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Aug 13, 2021 11:46am
176 Views
Post# 33700819

Institutional investor buying

Institutional investor buying

Stifel Financial Corp reports 7.49% increase in ownership of THTX / Theratechnologies Inc.

2021-08-13 - Stifel Financial Corp has filed a 13F-HR form disclosing ownership of 256,236 shares of Theratechnologies Inc. (US:THTX) with total holdings valued at $994,000 USD as of 2021-06-30. Stifel Financial Corp had filed a previous 13F-HR on 2021-05-14 disclosing 238,386 shares of Theratechnologies Inc. at a value of $921,000 USD. This represents a change in shares of 7.49 percent and a change in value of 7.93 percent during the quarter.

Price per share $3.87.

 

https://fintel.io/so/us/thtx/stifel-financial

 

UBS Group AG reports 16.04% increase in ownership of THTX / Theratechnologies Inc.

2021-08-13 - UBS Group AG has filed a 13F-HR form disclosing ownership of 87,144 shares of Theratechnologies Inc. (US:THTX) with total holdings valued at $338,000 USD as of 2021-06-30. UBS Group AG had filed a previous 13F-HR on 2021-05-12 disclosing 75,101 shares of Theratechnologies Inc. at a value of $290,000 USD. This represents a change in shares of 16.04 percent and a change in value of 16.55 percent during the quarter.

Price per share $3.87.

 

https://fintel.io/so/us/thtx/ubs

<< Previous
Bullboard Posts
Next >>